KR102162073B1 - 치매 또는 경도 인지 장애의 예방 또는 치료용 조성물의 제조에 사용하는 벤조산염의 용도 - Google Patents
치매 또는 경도 인지 장애의 예방 또는 치료용 조성물의 제조에 사용하는 벤조산염의 용도 Download PDFInfo
- Publication number
- KR102162073B1 KR102162073B1 KR1020177024853A KR20177024853A KR102162073B1 KR 102162073 B1 KR102162073 B1 KR 102162073B1 KR 1020177024853 A KR1020177024853 A KR 1020177024853A KR 20177024853 A KR20177024853 A KR 20177024853A KR 102162073 B1 KR102162073 B1 KR 102162073B1
- Authority
- KR
- South Korea
- Prior art keywords
- sodium benzoate
- dementia
- treatment
- test
- day
- Prior art date
Links
- 206010012289 Dementia Diseases 0.000 title claims abstract description 32
- 208000010877 cognitive disease Diseases 0.000 title abstract description 31
- 208000027061 mild cognitive impairment Diseases 0.000 title abstract description 26
- 239000000203 mixture Substances 0.000 title abstract description 4
- 150000001558 benzoic acid derivatives Chemical class 0.000 title abstract description 3
- 238000004519 manufacturing process Methods 0.000 title description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 45
- 238000011282 treatment Methods 0.000 claims abstract description 31
- 230000002265 prevention Effects 0.000 claims abstract 3
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 43
- 235000010234 sodium benzoate Nutrition 0.000 claims description 40
- 239000004299 sodium benzoate Substances 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 238000002360 preparation method Methods 0.000 abstract description 2
- 206010027175 memory impairment Diseases 0.000 abstract 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 27
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 27
- 238000012360 testing method Methods 0.000 description 27
- 230000000694 effects Effects 0.000 description 25
- 239000000902 placebo Substances 0.000 description 21
- 229940068196 placebo Drugs 0.000 description 21
- 230000001149 cognitive effect Effects 0.000 description 19
- 102000004674 D-amino-acid oxidase Human genes 0.000 description 15
- 108010003989 D-amino-acid oxidase Proteins 0.000 description 15
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 14
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 12
- 230000015654 memory Effects 0.000 description 12
- 229930195711 D-Serine Natural products 0.000 description 10
- 230000013016 learning Effects 0.000 description 10
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 9
- 238000012545 processing Methods 0.000 description 9
- 230000008859 change Effects 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 230000003936 working memory Effects 0.000 description 8
- 230000009286 beneficial effect Effects 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 230000007423 decrease Effects 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 229940050390 benzoate Drugs 0.000 description 5
- 210000001638 cerebellum Anatomy 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 230000000926 neurological effect Effects 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 210000003710 cerebral cortex Anatomy 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 230000005062 synaptic transmission Effects 0.000 description 4
- 208000000044 Amnesia Diseases 0.000 description 3
- 239000005711 Benzoic acid Substances 0.000 description 3
- 201000004569 Blindness Diseases 0.000 description 3
- 238000000729 Fisher's exact test Methods 0.000 description 3
- 238000000585 Mann–Whitney U test Methods 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 235000010233 benzoic acid Nutrition 0.000 description 3
- 230000019771 cognition Effects 0.000 description 3
- 230000003920 cognitive function Effects 0.000 description 3
- 208000030251 communication disease Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 210000001652 frontal lobe Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000001320 hippocampus Anatomy 0.000 description 3
- 238000012417 linear regression Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 210000001178 neural stem cell Anatomy 0.000 description 3
- 230000007310 pathophysiology Effects 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 208000031091 Amnestic disease Diseases 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 230000006986 amnesia Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000006999 cognitive decline Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 238000010832 independent-sample T-test Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000004766 neurogenesis Effects 0.000 description 2
- 210000004129 prosencephalon Anatomy 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 102100034112 Alkyldihydroxyacetonephosphate synthase, peroxisomal Human genes 0.000 description 1
- 208000024806 Brain atrophy Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000032862 Clinical Deterioration Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 1
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 125000000734 D-serino group Chemical group [H]N([H])[C@@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 101000799143 Homo sapiens Alkyldihydroxyacetonephosphate synthase, peroxisomal Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000027382 Mental deterioration Diseases 0.000 description 1
- 206010027374 Mental impairment Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 description 1
- 208000037048 Prodromal Symptoms Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000000848 angular dependent Auger electron spectroscopy Methods 0.000 description 1
- 230000002205 anti-dementic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000010237 calcium benzoate Nutrition 0.000 description 1
- 239000004301 calcium benzoate Substances 0.000 description 1
- HZQXCUSDXIKLGS-UHFFFAOYSA-L calcium;dibenzoate;trihydrate Chemical compound O.O.O.[Ca+2].[O-]C(=O)C1=CC=CC=C1.[O-]C(=O)C1=CC=CC=C1 HZQXCUSDXIKLGS-UHFFFAOYSA-L 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 230000037411 cognitive enhancing Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000019249 food preservative Nutrition 0.000 description 1
- 239000005452 food preservative Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000021474 generally recognized As safe (food) Nutrition 0.000 description 1
- 235000021472 generally recognized as safe Nutrition 0.000 description 1
- 235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 230000037417 hyperactivation Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 238000010988 intraclass correlation coefficient Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 230000003446 memory effect Effects 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000007979 neuropsychological functioning Effects 0.000 description 1
- 238000010855 neuropsychological testing Methods 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960004526 piracetam Drugs 0.000 description 1
- 230000026797 positive regulation of anti-apoptosis Effects 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 235000010235 potassium benzoate Nutrition 0.000 description 1
- 239000004300 potassium benzoate Substances 0.000 description 1
- 229940103091 potassium benzoate Drugs 0.000 description 1
- 210000002442 prefrontal cortex Anatomy 0.000 description 1
- 230000002360 prefrontal effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001003 psychopharmacologic effect Effects 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 231100000736 substance abuse Toxicity 0.000 description 1
- 201000006152 substance dependence Diseases 0.000 description 1
- 230000003956 synaptic plasticity Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000001521 two-tailed test Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 230000031836 visual learning Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/SG2014/000140 WO2015147742A1 (fr) | 2014-03-24 | 2014-03-24 | Utilisation d'un sel d'acide benzoïque dans la fabrication d'une composition pour prévenir ou traiter la démence ou un trouble cognitif léger |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020167003184A Division KR20160029837A (ko) | 2014-03-24 | 2014-03-24 | 치매 또는 경도 인지 장애의 예방 또는 치료용 조성물의 제조에 사용하는 벤조산염의 용도 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20170104658A KR20170104658A (ko) | 2017-09-15 |
| KR102162073B1 true KR102162073B1 (ko) | 2020-10-07 |
Family
ID=54196083
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020177024853A KR102162073B1 (ko) | 2014-03-24 | 2014-03-24 | 치매 또는 경도 인지 장애의 예방 또는 치료용 조성물의 제조에 사용하는 벤조산염의 용도 |
| KR1020167003184A KR20160029837A (ko) | 2014-03-24 | 2014-03-24 | 치매 또는 경도 인지 장애의 예방 또는 치료용 조성물의 제조에 사용하는 벤조산염의 용도 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020167003184A KR20160029837A (ko) | 2014-03-24 | 2014-03-24 | 치매 또는 경도 인지 장애의 예방 또는 치료용 조성물의 제조에 사용하는 벤조산염의 용도 |
Country Status (7)
| Country | Link |
|---|---|
| JP (1) | JP2016517866A (fr) |
| KR (2) | KR102162073B1 (fr) |
| AU (1) | AU2014386718B8 (fr) |
| CA (1) | CA2902498C (fr) |
| DE (1) | DE212014000063U1 (fr) |
| SG (1) | SG11201507188QA (fr) |
| WO (1) | WO2015147742A1 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3468944T3 (fi) * | 2016-06-13 | 2023-01-31 | Natriumbentsoaatin yhteiskiteitä ja niiden käyttöjä | |
| RU2022101542A (ru) | 2016-06-13 | 2022-02-03 | Сайньюрекс Интернэшнл (Тайвань) Корп. | Сокристаллы бензоата лития и их применения |
| US10336679B2 (en) * | 2016-10-24 | 2019-07-02 | Syneurx International (Taiwan) Corp. | Polymorphic forms of sodium benzoate and uses thereof |
| US11369579B2 (en) | 2016-10-24 | 2022-06-28 | Syneurx International (Taiwan) Corp. | Polymorphic forms of sodium benzoate and uses thereof |
| DE212018000171U1 (de) * | 2017-03-03 | 2019-12-04 | Excelsior Pharmatech Labs | Zusammensetzung zur Verwendung in der Prävention oder Behandlung von Autismus-Spektrum-Störungen umfassend ein Salz der Benzoesäure |
| TW202206061A (zh) * | 2017-11-22 | 2022-02-16 | 林潔欣 | 苯甲酸或其鹽及衍生物用於預防或治療憂鬱症之用途 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010085452A1 (fr) * | 2009-01-20 | 2010-07-29 | Los Angeles Biomedical Research Institute At Harbor - Ucla Medical Center | Acide sorbique et benzoïque et dérivés de celui-ci pour améliorer l'activité d'un produit neuropharmaceutique |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8601915D0 (en) * | 1986-01-27 | 1986-03-05 | Efamol Ltd | Pharmaceutical compositions |
| ZA200605384B (en) * | 2003-12-29 | 2007-10-31 | Sepracor Inc | Benzo[D]isoxazol-3-OL DAAO inhibitors |
| GB201111704D0 (en) * | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Novel compounds |
| US9212147B2 (en) * | 2011-11-15 | 2015-12-15 | Takeda Pharmaceutical Company Limited | Dihydroxy aromatic heterocyclic compound |
-
2014
- 2014-03-24 WO PCT/SG2014/000140 patent/WO2015147742A1/fr active Application Filing
- 2014-03-24 JP JP2016510654A patent/JP2016517866A/ja active Pending
- 2014-03-24 DE DE212014000063.7U patent/DE212014000063U1/de not_active Expired - Lifetime
- 2014-03-24 SG SG11201507188QA patent/SG11201507188QA/en unknown
- 2014-03-24 KR KR1020177024853A patent/KR102162073B1/ko active IP Right Grant
- 2014-03-24 KR KR1020167003184A patent/KR20160029837A/ko not_active Application Discontinuation
- 2014-03-24 CA CA2902498A patent/CA2902498C/fr active Active
- 2014-03-24 AU AU2014386718A patent/AU2014386718B8/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010085452A1 (fr) * | 2009-01-20 | 2010-07-29 | Los Angeles Biomedical Research Institute At Harbor - Ucla Medical Center | Acide sorbique et benzoïque et dérivés de celui-ci pour améliorer l'activité d'un produit neuropharmaceutique |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014386718A1 (en) | 2015-10-08 |
| DE212014000063U1 (de) | 2015-10-12 |
| JP2016517866A (ja) | 2016-06-20 |
| KR20160029837A (ko) | 2016-03-15 |
| CA2902498A1 (fr) | 2015-09-24 |
| AU2014386718B2 (en) | 2017-07-20 |
| CA2902498C (fr) | 2017-03-28 |
| WO2015147742A1 (fr) | 2015-10-01 |
| KR20170104658A (ko) | 2017-09-15 |
| SG11201507188QA (en) | 2015-10-29 |
| AU2014386718B8 (en) | 2017-12-07 |
| CA2902498F (fr) | 2015-09-24 |
| AU2014386718A8 (en) | 2017-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Skvarc et al. | The effect of N-acetylcysteine (NAC) on human cognition–A systematic review | |
| Lin et al. | Benzoate, a D-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease: a randomized, double-blind, placebo-controlled trial | |
| KR102162073B1 (ko) | 치매 또는 경도 인지 장애의 예방 또는 치료용 조성물의 제조에 사용하는 벤조산염의 용도 | |
| Vanicek et al. | Acute and subsequent continuation electroconvulsive therapy elevates serum BDNF levels in patients with major depression | |
| Askari et al. | The effects of folic acid and pyridoxine supplementation on characteristics of migraine attacks in migraine patients with aura: A double-blind, randomized placebo-controlled, clinical trial | |
| JP6608858B2 (ja) | 疲労を減少させるためまたは予防するためおよび認知機能を改善するためのｌ−カルニチン、その塩および誘導体の使用 | |
| Osborn et al. | Addressing potential role of magnesium dyshomeostasis to improve treatment efficacy for epilepsy: A reexamination of the literature | |
| Bhattacharya et al. | Attention enhancing effects of methylphenidate are age-dependent | |
| Menon et al. | Phenytoin toxicity: A case report | |
| JP6550426B2 (ja) | 認知症または軽度認知障害を予防または治療する組成物を製造するための安息香酸塩の使用 | |
| TWI573588B (zh) | 苯甲酸鹽用於製備治療失智症或輕度認知障礙之醫藥組成物的用途 | |
| Allali et al. | Gait and cognition: The impact of executive function. | |
| US20170216234A1 (en) | Benzoates for use in treating dementia | |
| Orsolini et al. | Long-acting paliperidone in Ekbom’s syndrome in Lewy body dementia: A case report | |
| Manzardo | Thiamine deficiency and alcoholism psychopathology | |
| Scott et al. | B vitamins influence vascular cognitive impairment | |
| Dubrovensky | Effects of a Cocktail Supplement of Ginkgo Biloba and Acai Extract on Cognitive Symptoms of Parkinson’s Disease | |
| VK et al. | The effect of vitamin K2-7 in peripheral neuropathy due to Vitamin B12 deficiency and/or diabetes mellitus | |
| Mamikonyan et al. | Neuropsychiatric symptoms in Parkinson’s disease dementia | |
| Campbell | Psychiatry Today and Tomorrow: Primum Non Nocere (First Do No Harm) | |
| Iannone et al. | USE OF ANTIDEPRESSANT MEDICATION DURING COGNITIVE AND DEPRESSIVE TREATMENT IN BRAZILIAN ELDERLY PATIENTS: A 180 DAY PROGRAM. | |
| D’Anci et al. | B vitamins in the prevention of cognitive decline and vascular dementia | |
| Schoemaker et al. | Adjunctive medication for difficult to treat symptoms in schizophrenia | |
| Starr | The Effects of HMG-CoA Reductase Inhibitors in the Prevention of Dementia in the Elderly Population | |
| Bastiaens | ADHD |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| E902 | Notification of reason for refusal | ||
| E902 | Notification of reason for refusal | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |